The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of radical cystectomy and increased risk of skeletal-related events in bone-metastatic urothelial carcinoma.
 
Nima Almassi
No Relationships to Disclose
 
Imaani J. Easthausen
No Relationships to Disclose
 
Soleen Ghafoor
No Relationships to Disclose
 
Paul J. Christos
No Relationships to Disclose
 
Timothy F. Donahue
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clinical Care Options; ClinicalMind; Intellisphere; Medscape; Peerview; Research To Practice; UpToDate; Vindico
Consulting or Advisory Role - Adicet Bio; Agensys; Astellas Pharma; AstraZeneca/MedImmune; Bayer; BioClin Therapeutics; Bristol-Myers Squibb; EMD Serono; Fortress Biotech; GlaxoSmithKline; Inovio Pharmaceuticals; Janssen Oncology; Lilly; Merck; Pharmacyclics; QED Therapeutics; Roche/Genentech; Seagen; Sensei Biotherapeutics; western oncolytics
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Mirati Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Seagen (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche
 
Azeez Farooki
Consulting or Advisory Role - Akrimax Pharmaceuticals; Alexion Pharmaceuticals; Amgen; Bayer/Onyx; Celgene; OncoMed